imatinib mesylate has been researched along with Anaplastic Oligodendroglioma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, SK; Brown, PD; Buckner, JC; Dixon, JG; Egorin, MJ; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Jenkins, R; Sarkaria, JN; Schwerkoske, J; Twohy, EL | 1 |
| Brennan, CW; Fomchenko, EI; Fujii, K; Holland, EC; Huse, JT; Ladanyi, M; Levine, RL; Nakada, M; Oka, H; Ozawa, T; Pedraza, A; Sasayama, T; Squatrito, M; Tandon, A; Utsuki, S; Wang, L; Yasui, Y | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, A; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ | 1 |
3 trial(s) available for imatinib mesylate and Anaplastic Oligodendroglioma
| Article | Year |
|---|---|
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
Topics: Antineoplastic Agents; Astrocytoma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Prognosis; Survival Rate; Tissue Distribution | 2019 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Central Nervous System Neoplasms; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2007 |
1 other study(ies) available for imatinib mesylate and Anaplastic Oligodendroglioma
| Article | Year |
|---|---|
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.
Topics: Amino Acid Sequence; Base Sequence; Benzamides; Gene Dosage; Gene Fusion; Gene Rearrangement; Glioblastoma; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Mutation; Oligodendroglioma; Phosphatidylinositol 3-Kinases; Phosphorylation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Transformation, Genetic | 2010 |